| Literature DB >> 30871537 |
K Schmitt1,2, C Lehner2,3, S Schuller3, G Schüpbach-Regula4, M Mevissen5, R Peter2, C R Müntener2, H Naegeli6, B Willi7.
Abstract
BACKGROUND: Antibiotic use in human and veterinary medicine is considered a main driver of antimicrobial resistance. Although guidelines to promote appropriate use of antimicrobials in veterinary patients have been developed, antibiotic overprescription is assumed to be a common problem. The goal of this study was to investigate antimicrobial use in cats in Switzerland with acute upper respiratory tract disease (aURTD), feline lower urinary tract disease (FLUTD) and abscesses, and to assess compliance of prescription with consensus guidelines. A total of 776 cases (aURTD, n = 227; FLUTD, n = 333; abscesses, n = 216) presented to two university hospitals and 14 private veterinary practices in Switzerland during 2016 were retrospectively evaluated. Clinical history, diagnostic work-up and antimicrobial prescription (class, dosage, duration) were assessed.Entities:
Keywords: Abscess; Acute upper respiratory tract disease; Antibiotic prescription; Antimicrobial stewardship; FLUTD; Feline lower urinary tract disease; Guidelines; Infection; Resistance
Mesh:
Substances:
Year: 2019 PMID: 30871537 PMCID: PMC6417182 DOI: 10.1186/s12917-019-1821-0
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Characteristics of cats with aURTDa, FLUTDb, and abscesses presented to university hospitals or private practices
| Parameter | aURTDª | FLUTDb | Abscesses | |||||
|---|---|---|---|---|---|---|---|---|
| University hospitals | Private practices | University hospitals | Private practices | Private practices | ||||
| Total number of cases | ||||||||
| Sex | Female | 17 (40%) | 82 (45%) | n.s.c | 43 (33%) | 97 (48%) | 0.006 | 64 (30%) |
| Male | 24 (55%) | 97 (53%) | 87 (67%) | 104 (51%) | 148 (68%) | |||
| Unknown | 2 (5%) | 5 (1%) | n.a.d | 0 (0%) | 2 (1%) | n.a.d | 4 (2%) | |
| Age (years) | Median (range; CIe) | 5 (0.042 –16; 2, 9) | 2 (0.06–19; 1, 4) | n.s.c | 7, (1–21; 7, 9) | 8 (0.17–20; 6, 9) | n.s.c | 7 (1–18; 6, 8) |
| Breed | Purebred | 11 (26%) | 33 (18%) | n.s.c | 36 (28%) | 33 (16%) | 0.026 | 14 (6%) |
| Mixed breed | 29 (67%) | 143 (78%) | 90 (69%) | 157 (77%) | 190 (88%) | |||
| Unknown | 3 (7%) | 8 (4%) | n.a.d | 4 (3%) | 13 (7%) | n.a.d | 12 (6%) | |
| Vaccinated | Yes | 14 (33%) | 28 (15%) | n.s.c | n.a.d | n.a.d | n.a.d | n.a.d |
| No | 17 (39%) | 50 (27%) | n.a.d | n.a.d | n.a.d | |||
| Unknown | 12 (28%) | 106 (58%) | n.a.d | n.a.d | n.a.d | n.a.d | n.a.d | |
ªaURTD, acute upper respiratory tract disease; bFLUTD, feline lower urinary tract disease; cn.s., not significant; dn.a., not applicable; eCI, confidence interval
Diagnostic work-up and antibiotic prescription in aURTDa cases presented to university hospitals or private practices
| Parameter | University hospitals | Private practices | ||
|---|---|---|---|---|
| Total number of cases | ||||
| Diagnostic work-up with PCRb | Yesc | 25 (58%) | 2 (1%) | <0.001 |
| At least one of the symptoms listed in the guidelinesd | Yesc | 29 (68%) | 37 (21%) | <0.001 |
| Unknown | 1 (3%) | 42 (23%) | ||
| Hospitalization | Yesc | 31 (72%) | 5 (3%) | <0.001 |
| Pre-treated with antibiotics | Yesc | 13 (30%) | 8 (4%) | <0.001 |
| Unknown | 2 (5%) | 4 (2%) | ||
| Antibiotic therapy | Yesc | 31 (72%) | 144 (78%) | n.s.e |
| Antibiotic classes | Potentiated aminopenicillins | 28 (90%) | 42 (29%) | <0.001 |
| Third generation cephalosporins | 2 (6%) | 47 (33%) | 0.002 | |
| Aminopenicillins | 1 (3%) | 40 (28%) | 0.002 | |
| Tetracyclines | 2 (6%) | 26 (18%) | n.s.e | |
| Fluoroquinolones | 1 (3%) | 6 (4%) | n.s.e | |
| Amphenicols | 0 (0%) | 3 (2%) | n.s.e | |
| Macrolides | 0 (0%) | 3 (2%) | n.s.e | |
| First generation cephalosporins | 0 (0%) | 1 (1%) | n.s.e | |
| Penicillins | 0 (0%) | 1 (1%) | n.s.e | |
| Combination or serial therapyf | Yesc | 4 (13%) | 21 (15%) | n.s.e |
| Critically important antibioticf | Yesc | 3 (10%) | 55 (38%) | 0.001 |
| Duration of therapy (days) | Median (range) | 12 (4–27) | 10 (4–37) | n.s.e |
| Justification scoref | 1 | 12 (28%) | 37 (20%) | n.s.e |
| 2 | 1 (2%) | 3 (2%) | n.s.e | |
| 3 | 26 (61%) | 22 (12%) | <0.001 | |
| 4 | 3 (7%) | 80 (43%) | <0.001 | |
| Judgement not possible | 1 (2%) | 42 (23%) | 0.001 |
aaURTD, acute upper respiratory tract disease; bPCR, polymerase chain reaction; cValues for the category “no” (reference group) are not shown; dPoor general condition, fever, lethargy and/ or anorexia; en.s., not significant; fAs defined in methods
Diagnostic work-up and antibiotic prescription in FLUTDa cases presented to university hospitals or private practices
| Parameter | University hospitals | Private practices | ||
|---|---|---|---|---|
| Total number of cases | ||||
| Urine analysis performed | Yesb | 119 (92%) | 55 (27%) | <0.001 |
| Sediment analysis | Yesb | 93 (72%) | 50 (25%) | <0.001 |
| Bacterial culture | Yesb | 113 (87%) | 20 (10%) | <0.001 |
| Confirmed bacterial etiologyc | Yesb | 45 (35%) | 16 (8%) | <0.001 |
| Hospitalization | Yesb | 90 (69%) | 30 (15%) | <0.001 |
| Pre-treated with antibiotics | Yesb | 23 (18%) | 4 (2%) | <0.001 |
| Unknown | 5 (4%) | 3 (2%) | ||
| Antibiotic therapy | Yesb | 85 (65%) | 115 (57%) | n.s.d |
| Antibiotic classes | Potentiated aminopenicillins | 71 (84%) | 50 (57%) | <0.001 |
| Third generation cephalosporins | 7 (8%) | 44 (38%) | <0.001 | |
| Fluoroquinolones | 5 (6%) | 20 (17%) | 0.017 | |
| Aminopenicillins | 1 (1%) | 22 (19%) | <0.001 | |
| First generation cephalosporins | 5 (6%) | 1 (1%) | n.s.d | |
| Amphenicols | 1 (1%) | 0 (0%) | n.s.d | |
| Tetracyclines | 1 (1%) | 0 (0%) | n.s.d | |
| Combination or serial therapye | Yesb | 6 (7%) | 20 (17%) | n.s.d |
| Critically important antibiotice | Yesb | 12 (14%) | 62 (54%) | <0.001 |
| Duration of therapy (days) | Median (range) | 13 (1 –56) | 9 (1 –42) | 0.012 |
| Justification scoree | 1 | 57 (44%) | 24 (12%) | <0.001 |
| 2 | 1 (1%) | 0 (0%) | n.s.d | |
| 3 | 22 (17%) | 9 (4%) | <0.001 | |
| 4 | 39 (30%) | 11 (6%) | <0.001 | |
| Judgement not possible | 11 (8%) | 159 (78%) | <0.001 |
aFLUTD, feline lower urinary tract disease; bValues for the category “no” (reference group) are not shown; cDefined as either positive urine sediment analysis or positive bacterial culture; dn.s., not significant; eAs defined in methods
Clinical signs, wound treatment and antibiotic prescription in cases with abscesses presented to private practices
| Parameter | Private practices | |
|---|---|---|
| Total number of cases | ||
| At least one of the symptoms listed in the guidelinesa | Yesb | 65 (30%) |
| Unknown | 85 (39%) | |
| Local wound treatment | Yesb | 156 (72%) |
| Unknown | 12 (6%) | |
| Drain placement | Yesb | 33 (15%) |
| Antibiotic therapy | Yesb | 207 (96%) |
| Antibiotic classes | Potentiated aminopenicillins | 132 (64%) |
| Third generation cephalosporins | 52 (25%) | |
| Aminopenicillins | 50 (24%) | |
| First generation cephalosporins | 12 (6%) | |
| Fluoroquinolones | 5 (3%) | |
| Lincosamides | 4 (2%) | |
| Penicillins | 1 (1%) | |
| Combination or serial therapyc | Yesb | 48 (24%) |
| Critically important antibioticc | Yesb | 57 (28%) |
| Duration of therapy (days) | 7 (1 –24) | |
| Justification scorec | 1 | 36 (17%) |
| 2 | 16 (7%) | |
| 3 | 14 (7%) | |
| 4 | 65 (30%) | |
| Judgement not possible | 85 (39%) |
aSigns of generalization, poor general condition, severely contaminated wounds, and/ or proximity to delicate tissues; bValues for the category “no” (reference group) are not shown; cAs defined in methods
Inclusion and exclusion criteria and search terms for aURTDa, FLUTDb and abscesses
| Indication | Inclusion criteria | Exclusion criteria | Search terms |
|---|---|---|---|
| aURTDª | Nasal discharge with infectious or unknown etiology lasting no longer than 2 weeks | Evidence of fungal infection, neoplasia or involvement of the lower respiratory tract | Upper respiratory tract infection, rhinotracheitis, rhinitis, sinusitis, nasal discharge, sneezing, coughing, stridor, dyspnea, tachypnea, cat flu, herpes, calici, mycoplasma, chlamydia, laryngitis |
| FLUTDb | Stranguria, pollakiuria, periuria, pigmenturia or dysuria and a diagnosis of bacterial cystitis, bladderstones, urethrastones, urethral plugs, idiopathic cystitis or cystitis of unknown origin | Involvement of the upper urinary tract | Lower urinary tract disease, FLUTDb, pollakiuria, polyuria, anuria, stranguria, dysuria, hematuria, bloody urine, urinary stones, bladder stones, urolithiasis, concrements, cystitis, urethra obstruction, urinary tract infection, UTI, urinary incontinence |
| Abscess | Bite abscesses or abscesses of unknown origin | Anal gland abscesses, tooth root abscesses, foreign body abscesses | Abscess, bite wound, bite, pus |
ªaURTD, acute upper respiratory tract disease; bFLUTD, feline lower urinary tract disease
Consensus guidelines [40, 41] used to evaluate prudent use of antimicrobials
| Indication | Comment | Antibiotic | Dosage (mg/kg) | Application frequency | Treatment duration (days) |
|---|---|---|---|---|---|
| aURTDa | Antibiotic therapy is only indicated if poor general condition, fever, lethargy and/or anorexia are present | Doxycycline | 10 / 5 | SIDb/BIDc | 5–14 |
| Amoxicillin | 15–20 | BIDc/TIDd | 5–14 | ||
| FLUTDe | Complicated UTIf are defined as infections that are caused by anatomical or functional changes or disorders of the immune system | Uncomplicated UTIf: | |||
| Amoxicillin | 11–15 | BIDc/TIDd | 5–7 | ||
| Complicated UTIf: | |||||
| Amoxicillin/Clavulanic acid | 12.5–20 | BIDc/TIDd | 5–28 | ||
| Abscess | Antibiotic therapy is only indicated if signs of generalization, poor general condition, severely contaminated wounds, and/or proximity to delicate tissues (e.g., joints) are present | Amoxicillin | 15–20 | BIDc | 5–7 |
| Amoxicillin/Clavulanic acid | 12.5–20 | BIDc | 5–7 | ||
| Cefalexin | 20–30 | BIDc/TIDd | 5–7 | ||
| Clindamycin | 10–15 | BIDc | 5–7 | ||
| Cefazolin | 20 | BIDc | 5–7 |
aaURTD, acute upper respiratory tract disease; bSID, once daily; cBID, twice daily; dTID, three times daily; eFLUTD, feline lower urinary tract disease; fUTI, urinary tract infection
Justification score (JSa) used to compare antimicrobial prescription to consensus guidelines
| Justification score | Explanation |
|---|---|
| 1 | Indication, antimicrobial class, dose and treatment duration in accordance with the guidelines |
| 2 | Antibiotic therapy indicated but durationb and/or dosec of treatment not in accordance with the guidelines |
| 3 | Antibiotic therapy indicated but antimicrobial class not in accordance with the guidelinesd |
| 4 | Complete discrepancy with the guidelines, i.e. antibiotics were prescribed without indication or, conversely, antibiotics were not prescribed despite being indicated |
aModified from De Pestel et al., 2014 [70]; bA margin of 1 day shorter or longer was tolerated; cA deviation of up to 20% above or below the recommended dose was accepted; dEach case was scored only once. If the dose or duration of treatment as well as the antibiotic class were deviating from the guidelines, the case was categorized as JS-3